Opendata, web and dolomites


NeurescueTM: Computer- controlled aortic occlusion device for the treatment of cardiac arrest

Total Cost €


EC-Contrib. €






 CAtALySt project word cloud

Explore the words cloud of the CAtALySt project. It provides you a very rough idea of what is the project "CAtALySt" about.

severe    preservation    roll    with    projected    patient    damage    odense    france    algorithm    company    introduction    denmark    pressure    below    united    2030    function    aggregated    combines    aorta    total    revenue    health    neurescuetm    university    price    2020    proposition    clinical    worldwide    profitable    proposes    organs    234m    outside    critical    40    perfusion    commercial    barriers    cardiac    rate    intervention    generation    incidence    patients    solution    rates    roject    hospital    paris    vital    million    competitive    arrests    back    surpass    synergy    resuscitation    samu    89    accuracy    portability    neurescue    works    normal    premises    emergency    germany    survival    marking    portable    demonstration    post    building    de    market    sudden    holding    predicted    neur    chu    radically    burden    inside    unrivalled    adoption    catalyst    data    device    public    medical    gathering    business    sensor    probability    accurate    sca    standard    position    23    computer    assistance    ready    validation    window    ce    necker    light    tissue    safe    heart    broad    changing    episodes    run    aortic    brain    blood    10    time    game    occlusion    aps   

Project "CAtALySt" data sheet

The following table provides information about the project.


Organization address
address: NJALSGADE 76
postcode: 2300
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Denmark [DK]
 Project website
 Total cost 2˙331˙787 €
 EC max contribution 1˙632˙251 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-2
 Funding Scheme SME-2
 Starting year 2018
 Duration (year-month-day) from 2018-08-01   to  2021-01-31


Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    NEURESCUE APS DK (KOBENHAVN) coordinator 1˙632˙251.00


 Project objective

With a worldwide incidence expected to increase from 9,23 million cases by 2020 to 10,89 million cases by 2030, Sudden Cardiac Arrests (SCA) episodes are today recognized as a public health problem leading to severe brain tissue damage with survival rates below 10%. Neurescue Aps (NEUR) proposes to address the SCA burden by bringing to light a game changing solution - NeurescueTM – capable of extending the critical time window necessary to bring a SCA patient back to normal heart function, and therefore holding the potential to radically improve the emergency assistance provided to SCA patients, allowing for 20- 40% of increase in the survival rate of SCA patients. Due to an algorithm-run sensor technology which enables a safe and accurate computer-controlled aortic occlusion, NeurescueTM is a portable medical device that, not only increases the blood perfusion pressure necessary for vital organs preservation (i.e. brain and heart), but also works in synergy with standard resuscitation procedures increasing their probability of success. NeurescueTM is the only device in the market that combines portability with the accuracy required for a safe medical intervention (i.e. aorta occlusion) to SCA patients both inside and outside the hospital premises. With a price-competitive technology and with an unrivalled value proposition, NEUR is in a strong position to build a profitable business. Building on the project activities, NeurescueTM the device is projected to be ready for commercial roll-out by 2020 with a predicted total aggregated revenue for the company of over €234M throughout the 5 years post- roject. CAtALySt project aims to surpass the main market barriers associated with the market introduction of NeurescueTM, namely gathering data for CE-marking and broad clinical demonstration for market awareness and to ensure end-user medical adoption. Clinical validation will be held at Odense University Hospital in Denmark, and further clinical evidence generation at Hospital SAMU de Paris CHU Necker in France, a leading university hospital in Germany, and a leading university hospital in the United States.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "CATALYST" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email ( and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "CATALYST" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

CoLumbo (2019)


Read More  

SIRA (2019)

A disruptive machine to enable mass production of composite parts

Read More  

ClosedToe (2020)

Sock toe closing system for circular knitting machines

Read More